PDX Pharmaceuticals Secures Additional Investment from the Kuni Foundation to Advance New Cancer-Fighting Precision Therapies
Portland, Oregon — PDX Pharmaceuticals, a privately held company developing first-in-class nanotechnology-based therapies for treating cancer, received a second round of Series A funding in the amount of $2 million from the Kuni Foundation. PDX Pharmaceuticals, a startup that originated in the Biomedical Engineering Department of Oregon Health & Science University (OHSU) in collaboration with the Knight Cancer Institute, has developed a new class of therapeutics based on co-delivery of siRNA and drugs on immuno-nanoparticles. The
We partner with families to provide loving, supportive adult care home for adults with developmental disabilities. Our unique approach is to create a safe, active and healthy environment that is rich in community interaction and family involvement. We are committed to providing a beautiful space for our residents to thrive – to make friends, work, play, volunteer and enjoy life.
Funding Supports Emerging and Established Cancer Research Leaders and Innovative Programs for Individuals who Experience Intellectual Challenges Through its Imagination Grants Program, the Kuni Foundation recently awarded $1.3 million in funding for 23 initiatives that advance ground-breaking cancer research and programs that enhance the well-being and inclusion of individuals who experience intellectual and developmental disabilities (I/DD). The Foundation’s Board of
Special Olympics Oregon (SOOR) received a three-year commitment of $100,000 per year from The Kuni Foundation. The funding will support the critical services Special Olympics Oregon provides to enhance the lives of thousands of children and adults living with intellectual disabilities across the state of Oregon. “We are honored to support the important work of Special Olympics Oregon, which creates
Vancouver, Washington – The Kuni Foundation is pleased to announce the appointment of John G. Hunter, MD to the organization’s Board of Directors. Dr. Hunter serves as Executive Vice President of Oregon Health & Science University and Chief Executive Officer of OHSU Health, which includes OHSU Hospital, Doernbecher Children’s Hospital, Tuality Healthcare and Adventist Health Portland. “We are honored to